Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06043323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Name: A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma — clinical trial record (NCT06043323)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorM.D. Anderson Cancer Center

Started2024-01-08

View on ClinicalTrials.gov ↗

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

Amendment history 1 change detected by DataLookout

2026-09-05

Primary completion pushed: 2026-09-01 → 2028-09-01

Trial Details

NCT Number	NCT06043323
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Follicular Lymphoma
Enrollment	20 participants
Start Date	2024-01-08
Primary Completion	2028-09-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-04